title: Fever-range whole body hyperthermia increases the number of perfused tumor blood vessels and therapeutic efficacy of liposomally encapsulated doxorubicin.
abstract: OBJECTIVE
  Two major questions were addressed: (1) Can fever-range whole body hyperthermia (FR-WBH) affect the number of perfused tumor blood vessels? (2) Can pre-treatment with FR-WBH improve accumulation or anti-tumor efficacy of doxorubicin or DOXIL (liposomal doxorubicin)?
  
  
  METHODS
  Perfused blood vessels were visualized by intravenous injection of the fluorescent dye (DiOC7(3)) and the number of labeled vessels in tumors and normal organs of unheated mice and those previously heated to 39.5 degrees C for 6 hours were compared. Using three animal tumor models (one syngeneic murine model and two human tumor xenografts in SCID mice) we also compared tumor growth and amount of intratumoral doxorubicin (given as free drug or as DOXIL) in control mice or those given pre-treatment with FR-WBH.
  
  
  RESULTS
  FR-WBH had no effect on the number of CD-31 labeled blood vessels. However, in tumors, but not in normal organs of the same animals, FR-WBH resulted in a significant increase in those blood vessels which could take up dye over a prolonged period of time after heating. There was also an increase in DOXIL uptake in the tumors of mice given FR-WBH prior to drug injection as well as enhanced therapeutic efficacy in all three tumor models.
  
  
  CONCLUSIONS
  FR-WBH increases the number of perfused blood vessels in tumors over a prolonged period following FR-WBH and thus may be useful for improving tumor targeting of cancer therapeutics. We discuss these data in relation to long-conserved thermoregulatory features in normal vasculature, which may be deficient in tumor vasculature.
authors.affiliation: Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
authors.forename: Yan
authors.initials: Y
authors.lastname: Xu
authors.forename: Jason
authors.initials: J
authors.lastname: Choi
authors.forename: Bonnie
authors.initials: B
authors.lastname: Hylander
authors.forename: Arindam
authors.initials: A
authors.lastname: Sen
authors.forename: Sharon S
authors.initials: SS
authors.lastname: Evans
authors.forename: William G
authors.initials: WG
authors.lastname: Kraybill
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Repasky
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D016022:Case-Control Studies; D045744:Cell Line, Tumor / Q000637:transplantation; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D005334:Fever; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin